There is an undeniable cycle to nature. Leaves turn color and fall, birds migrate across continents, and stocks fall after the annual American Society of Clinical Oncology (ASCO) meeting. Making matters perhaps a bit worse this year, there were very few presentations that really stood out and not an abundance of positive news for investors to process. As is so often the case, though, there was a lot of buying momentum into the meeting and Wall Street is once again playing out the "buy the rumor, sell the news" meme.

Tutorial: The Industry Handbook

The Best in Show - YMI and Exelixis
The most interesting presentations arguably belonged to YM BioSciences (AMEX:YMI) and Exelixis (Nasdaq:EXEL). It is also par for the course, though, that neither presentation was completely "clean" and investors still have a lot of questions about the future of the respective drugs.

For YMI, it was all about Phase 1/2 data from the JAK-2 inhibitor CYT387 in myelofibrosis. Myelofibrosis is a rare condition and one that frequently leads to an enlarged spleen and/or anemia. This relatively small study showed good spleen response and suggested benefit in counteracting anemia. Unfortunately, this is the prime question about CYT387 - is the anemia benefit "real"? If so, this could be a drug worth hundreds of millions of dollars, but investors are just going to have to wait for further studies to confirm (or disprove) this benefit. On an encouraging note, the company seems to be taking a very smart approach to the clinical development of the drug. (For more, see Measuring The Medicine Makers.)

For Exelixis, the real excitement was about Phase 2 data for cabozantinib in seriously ill prostate cancer patients. The trial showed a meaningful reduction in tumor progression, and bone scans showed that 76% of the patients were partially or completely cleared of bone lesions. The drug also seemed to have a very significant benefit to reducing pain (metastasis of prostate cancer into the bone is excruciating). (For more, see Drug Companies With Tasty Medicine.)

Now the bad news. There have been deaths associated with this drug (1 tied to the drug in the prostate study) and it seems like the mechanism of action makes that almost inevitable. Also, the company has not designed the studies to show survival benefit, and it could be challenging to secure FDA approval without that data - particularly as Bristol-Myers (NYSE:BMY) showed data at ASCO from its Phase 3 prostate drug candidate (alpharadin - licensed from Algeta) that did point to a survival benefit.

Controversy Still Swirling Around Neoprobe
Neoprobe (Nasdaq:NEOP) is a pretty small company, but the controversy around the stock and its drug Lymphoseek is large indeed. Lymphoseek is actually an imaging agent, but the approval process is essentially identical as if it were a drug. The good news is that Lymphoseek did exceed the endpoints of its Phase 3 study and seems to be a highly sensitive agent. It also would seem to have non-trivial safety benefits and an improved administration profile over the standard of care.

Unfortunately, there is controversy about whether the company has run the proper trials. The trials have compared Lymphoseek to an FDA-approved alternative when the actual standard of care is to use a combination of that approved alternative (vital blue dye) and a colloid. The question, then, is whether Neoprobe can establish superior efficacy in a real world setting, though the safety profile may mitigate that argument. It's also worth noting that while Lymphoseek would certainly be significant to Neoprobe, the list of breakaway biotech successes based on imaging compounds is pretty sparse. (For more, see A Primer On The Biotech Sector.)

Other Data of Note
Bristol-Myers also reported very encouraging data on Yervoy (ipilimumab) in skin cancer; so much so that it could dominate the "wild type BRAF" melanoma market. Incyte (Nasdaq:INCY) and partner Novartis (NYSE:NVS) reported strong data on their myelofibrosis drug ruxolitinib. In contrast to YMI's drug, there is very good spleen response with ruxolitinib, but not much anemia benefit. Nevertheless, this drug is years ahead of YMI's compound and the two companies have filed for U.S. approval.

Other reports of some note include data from Celgene (Nasdaq:CELG) that was supportive of Revlimid but negative for Abraxane (showing a better response rate than paclitaxel, but no survival benefit in lung cancer) and solid data from Sanofi's (NYSE:SNY) semuloparin, an ultra-low weight heparin targeted at preventing venous clots in cancer patients. (For more, see Pharmaceutical Phenoms: America's Best-Selling Medicines.)

The Bottom Line
Many biotech investors seemed puzzled by Monday's post-ASCO declines, but they should take some solace in the fact that this is a very routine occurrence. While there are still a lot of questions for investors in stocks like YMI, Exelixis, and Neoprobe, bulls can certainly find some positive news to reinforce their thesis. As always, the key to successful biotech investing is diversification, staying power and due diligence. (For more, see The Ups And Downs Of Biotechnology.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  2. Stock Analysis

    Analyzing Dish Network's Return on Equity (ROE) (DISH, TWC)

    Analyze Dish Network's return on equity (ROE), understand why it has vacillated so greatly in recent years and learn what factors are influencing it.
  3. Fundamental Analysis

    5 Must-Have Metrics For Value Investors

    Focusing on certain fundamental metrics is the best way for value investors to cash in gains. Here are the most important metrics to know.
  4. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  5. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  6. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  7. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  8. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  9. Stock Analysis

    The Top 5 Micro Cap Alternative Energy Stocks for 2016 (AMSC, SLTD)

    Follow a cautious approach when purchasing micro-cap stocks in the alternative energy sector. Learn about five alternative energy micro-caps worth considering.
  10. Stock Analysis

    Analyzing Porter's Five Forces on Under Armour (UA)

    Learn about Under Armour and how it differentiates itself in the competitive athletic apparel industry in light of the Porter's Five Forces Model.
RELATED FAQS
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center